Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors

Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors

Background: TQ-B3101 is a novel kinase inhibitor currently in development for the treatment of advanced malignant solid tumor and relapsed or refractory ALK-positive anaplastic large cell lymphoma.Methods: A population pharmacokinetic model was developed using data collected from a Phase 1 study and...

Full description

Bibliographic Details
Main Authors: Fen Yang, Huali Wu, Yunhai Bo, Ye Lu, Hong Pan, Su Li, Qin Lu, Simin Xie, Harry Liao, Bing Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Pharmacology
Subjects:
TQ-B3101
pediatric
pharmacokinetic
model
solid tumor
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.782518/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.782518/full

Similar Items